Literature DB >> 32275256

Vademecum for the treatment of people with COVID-19. Edition 2.0, 13 March 2020.

- Lombardy Section Italian Society Infectious And Tropical Diseases.   

Abstract

The spread of COVID-19 epidemic in Italy, and particularly in Lombardy determined the need to standardize the therapeutic approach in order to offer the same indications for all hospitals in Lombardy. However, no specific drug has been previously approved for the COVID-19 treatment. The Lombardy Section of the Italian Society of Infectious and Tropical Diseases provided this «vademecum» with the aim to explore the current evidence about the drugs likely to be efficacious in the treatment of COVID-19. Moreover, a multidisciplinary group including critical care specialists has been created in order to provide indications about supporting measures and the use of steroids. A new grading scale has been proposed to help patients' stratification according to the severity of the respiratory conditions. Lastly, a collaborating group with immunologists and rheumatologists has been built with the aim of providing some guidance about the use of tocilizumab, a promising option for the treatment of the hyperinflammatory state occurring in most patients affected by COVID-19.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32275256

Source DB:  PubMed          Journal:  Infez Med        ISSN: 1124-9390


  32 in total

1.  Bronchoalveolar lavage-detected SARS-CoV-2 infection in presence of serial negative nasopharyngeal swabs: a case report.

Authors:  Grazia Caci; Fabrizio Minervini; Carsten Fechner; Justus E Roos; Ellen C Obermann; Andrea Azzola
Journal:  Ann Transl Med       Date:  2021-04

2.  Vitamin D deficiency, secondary hyperparathyroidism and respiratory insufficiency in hospitalized patients with COVID-19.

Authors:  G Mazziotti; E Lavezzi; A Brunetti; M Mirani; G Favacchio; A Pizzocaro; M T Sandri; A Di Pasquale; A Voza; M Ciccarelli; A G Lania
Journal:  J Endocrinol Invest       Date:  2021-03-05       Impact factor: 5.467

3.  Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs.

Authors:  H N Chakravarti; A Nag
Journal:  J Endocrinol Invest       Date:  2020-06-27       Impact factor: 4.256

4.  Epidemiological and Clinical Characterization of Superinfections in Critically Ill Coronavirus Disease 2019 Patients.

Authors:  Liana Signorini; Giovanni Moioli; Stefano Calza; Evelyn Van Hauwermeiren; Silvia Lorenzotti; Giovanni Del Fabro; Giulia Renisi; Paola Lanza; Barbara Saccani; Giulia Zambolin; Nicola Latronico; Francesco Castelli; Sergio Cattaneo; John C Marshall; Alberto Matteelli; Simone Piva
Journal:  Crit Care Explor       Date:  2021-06-11

5.  A single center experience of intravenous immunoglobulin treatment in Covid-19.

Authors:  Ahmet Omma; Abdulsamet Erden; Berkan Armağan; Serdar Can Güven; Özlem Karakaş; Enes Seyda Şahiner; Deniz Erdem; Seval İzdeş; İhsan Ateş; Orhan Küçükşahin
Journal:  Int Immunopharmacol       Date:  2021-06-14       Impact factor: 5.714

Review 6.  Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic.

Authors:  Bogna Grygiel-Górniak
Journal:  Clin Rheumatol       Date:  2021-07-03       Impact factor: 3.650

7.  Early-stage predictors of the acute phase duration in uncomplicated COVID-19 pneumonia.

Authors:  Claudio Carallo; Fabiola Pugliese; Cesare Tripolino; Lorenza Lenzi; Chiara Oliveri; Giada Fasani; Giovanni M Guarrera; Walter Spagnolli; Susanna Cozzio
Journal:  J Med Virol       Date:  2020-07-21       Impact factor: 20.693

Review 8.  Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID-19 pandemic.

Authors:  Marco Infante; Camillo Ricordi; Andrea Fabbri
Journal:  J Diabetes       Date:  2020-06-11       Impact factor: 4.530

9.  First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19.

Authors:  Damir Muhović; Jelena Bojović; Ana Bulatović; Batrić Vukčević; Marina Ratković; Ranko Lazović; Brigita Smolović
Journal:  Liver Int       Date:  2020-06-01       Impact factor: 8.754

10.  Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study.

Authors:  Andrea Giacomelli; Gabriele Pagani; Anna L Ridolfo; Letizia Oreni; Federico Conti; Laura Pezzati; Lucia Bradanini; Giacomo Casalini; Cinzia Bassoli; Valentina Morena; Simone Passerini; Giuliano Rizzardini; Chiara Cogliati; Elisa Ceriani; Riccardo Colombo; Stefano Rusconi; Cristina Gervasoni; Dario Cattaneo; Spinello Antinori; Massimo Galli
Journal:  J Med Virol       Date:  2020-09-28       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.